

# Guy Boivin

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8630293/guy-boivin-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

252  
papers

11,518  
citations

60  
h-index

97  
g-index

271  
ext. papers

13,166  
ext. citations

7.4  
avg, IF

6.47  
L-index

#	Paper	IF	Citations
252	Viral Interference between Respiratory Viruses.. <i>Emerging Infectious Diseases</i> , <b>2022</b> , 28, 273-281	10.2	5
251	Duration of isolation and contagiousness in COVID-19 patients receiving tocilizumab and dexamethasone: a case series.. <i>Infection Control and Hospital Epidemiology</i> , <b>2022</b> , 1-14	2	0
250	Single-cell transcriptomics of the ventral posterolateral nucleus-enriched thalamic regions from HSV-1-infected mice reveal a novel microglia/microglia-like transcriptional response.. <i>Journal of Neuroinflammation</i> , <b>2022</b> , 19, 81	10.1	1
249	In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes.. <i>Antiviral Research</i> , <b>2022</b> , 202, 105328	10.8	
248	DNA polymerases of herpesviruses and their inhibitors. <i>The Enzymes</i> , <b>2021</b> , 50, 79-132	2.3	1
247	Differential impact of various substitutions at codon 715 in region II of HSV-1 and HCMV DNA polymerases. <i>Antiviral Research</i> , <b>2021</b> , 188, 105046	10.8	2
246	Genetics of symptom remission in outpatients with COVID-19. <i>Scientific Reports</i> , <b>2021</b> , 11, 10847	4.9	1
245	Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2021</b> , 65, e0039021	5.9	1
244	Inhibition of the 3CL Protease and SARS-CoV-2 Replication by Dalcetrapib. <i>ACS Omega</i> , <b>2021</b> , 6, 16584-16591	5.9	4
243	Human Respiratory Syncytial Virus-Induced Immune Signature of Infection Revealed by Transcriptome Analysis of Clinical Pediatric Nasopharyngeal Swab Samples. <i>Journal of Infectious Diseases</i> , <b>2021</b> , 223, 1052-1061	7	1
242	Fitness of influenza A and B viruses with reduced susceptibility to baloxavir: A mini-review. <i>Reviews in Medical Virology</i> , <b>2021</b> , 31, e2175	11.7	3
241	Antiviral Drugs Against Herpesviruses. <i>Advances in Experimental Medicine and Biology</i> , <b>2021</b> , 1322, 1-30	3.6	2
240	RSV and HMPV Infections in 3D Tissue Cultures: Mechanisms Involved in Virus-Host and Virus-Virus Interactions. <i>Viruses</i> , <b>2021</b> , 13,	6.2	6
239	Microglia are involved in phagocytosis and extracellular digestion during Zika virus encephalitis in young adult immunodeficient mice. <i>Journal of Neuroinflammation</i> , <b>2021</b> , 18, 178	10.1	1
238	Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. <i>Lancet Respiratory Medicine</i> , <b>2021</b> , 9, 924-932	35.1	91
237	A novel bioluminescent herpes simplex virus 1 for in vivo monitoring of herpes simplex encephalitis. <i>Scientific Reports</i> , <b>2021</b> , 11, 18688	4.9	1
236	Zika virus and impact on male fertility <b>2021</b> , 289-298		

235	Infectivity of healthcare workers diagnosed with coronavirus disease 2019 (COVID-19) approximately 2 weeks after onset of symptoms: A cross-sectional study. <i>Infection Control and Hospital Epidemiology</i> , <b>2021</b> , 1-3	2	6
234	Effects of Different Drug Combinations in Immunodeficient Mice Infected with an Influenza A/H3N2 Virus. <i>Microorganisms</i> , <b>2020</b> , 8,	4.9	2
233	Hypersusceptibility of Human Cytomegalovirus to Foscarnet Induced by Mutations in Helices K and P of the Viral DNA Polymerase. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2020</b> , 64,	5.9	4
232	Age-stratified burden of pneumococcal community acquired pneumonia in hospitalised Canadian adults from 2010 to 2015. <i>BMJ Open Respiratory Research</i> , <b>2020</b> , 7,	5.6	11
231	Characterization of contemporary influenza B recombinant viruses harboring mutations of reduced susceptibility to baloxavir marboxil, in vitro and in mice. <i>Antiviral Research</i> , <b>2020</b> , 179, 104807	10.8	5
230	Immunomodulatory Strategies in Herpes Simplex Virus Encephalitis. <i>Clinical Microbiology Reviews</i> , <b>2020</b> , 33,	34	14
229	Modified cyclodextrins as broad-spectrum antivirals. <i>Science Advances</i> , <b>2020</b> , 6, eaax9318	14.3	87
228	Frailty Hinders Recovery From Influenza and Acute Respiratory Illness in Older Adults. <i>Journal of Infectious Diseases</i> , <b>2020</b> , 222, 428-437	7	12
227	Evaluation of pre- and post-fusion Human metapneumovirus F proteins as subunit vaccine candidates in mice. <i>Vaccine</i> , <b>2020</b> , 38, 2122-2127	4.1	1
226	Novel calixarene-based surfactant enables low dose split inactivated vaccine protection against influenza infection. <i>Vaccine</i> , <b>2020</b> , 38, 278-287	4.1	5
225	In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses. <i>Viruses</i> , <b>2020</b> , 12,	6.2	5
224	An Early Microglial Response Is Needed To Efficiently Control Herpes Simplex Virus Encephalitis. <i>Journal of Virology</i> , <b>2020</b> , 94,	6.6	9
223	Cytomegalovirus Seropositivity Is Associated With Increased Microbial Translocation in People Living With Human Immunodeficiency Virus and Uninfected Controls. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 71, 1438-1446	11.6	27
222	Impact of the Baloxavir-Resistant Polymerase Acid I38T Substitution on the Fitness of Contemporary Influenza A(H1N1)pdm09 and A(H3N2) Strains. <i>Journal of Infectious Diseases</i> , <b>2020</b> , 221, 63-70	7	29
221	Pandemics Throughout History. <i>Frontiers in Microbiology</i> , <b>2020</b> , 11, 631736	5.7	89
220	Droplet Digital PCR and Immunohistochemistry Techniques to Detect Zika Virus in the Central Nervous System of Mice. <i>Methods in Molecular Biology</i> , <b>2020</b> , 2142, 41-57	1.4	2
219	Effectiveness of Influenza Vaccination on Hospitalizations and Risk Factors for Severe Outcomes in Hospitalized Patients With COPD. <i>Chest</i> , <b>2019</b> , 155, 69-78	5.3	36
218	Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance. <i>Antiviral Research</i> , <b>2019</b> , 163, 91-105	10.8	40

217	OVX836 a recombinant nucleoprotein vaccine inducing cellular responses and protective efficacy against multiple influenza A subtypes. <i>Npj Vaccines</i> , <b>2019</b> , 4, 4	9.5	11
216	Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis. <i>Journal of Infectious Diseases</i> , <b>2019</b> , 220, 1302-1306	7	7
215	Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, Canada. <i>Emerging Infectious Diseases</i> , <b>2019</b> , 25, 838-840	10.2	5
214	Design and Validation with Influenza A Virus of an Aerosol Transmission Chamber for Ferrets. <i>International Journal of Environmental Research and Public Health</i> , <b>2019</b> , 16,	4.6	5
213	Human metapneumovirus activates NOD-like receptor protein 3 inflammasome via its small hydrophobic protein which plays a detrimental role during infection in mice. <i>PLoS Pathogens</i> , <b>2019</b> , 15, e1007689	7.6	2
212	Repurposing of Drugs as Novel Influenza Inhibitors From Clinical Gene Expression Infection Signatures. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 60	8.4	29
211	Zika-Induced Male Infertility in Mice Is Potentially Reversible and Preventable by Deoxyribonucleic Acid Immunization. <i>Journal of Infectious Diseases</i> , <b>2019</b> , 219, 365-374	7	8
210	Characterization of cellular transcriptomic signatures induced by different respiratory viruses in human reconstituted airway epithelia. <i>Scientific Reports</i> , <b>2019</b> , 9, 11493	4.9	18
209	The Val430Ile neuraminidase (NA) substitution, identified in influenza B virus isolates, impacts the catalytic 116Arg residue causing reduced susceptibility to NA inhibitors. <i>Antiviral Research</i> , <b>2019</b> , 170, 104561	10.8	2
208	<i>Streptococcus pneumoniae</i> serotype 3 is masking PCV13-mediated herd immunity in Canadian adults hospitalized with community acquired pneumonia: A study from the Serious Outcomes Surveillance (SOS) Network of the Canadian immunization research Network (CIRN). <i>Vaccine</i> , <b>2019</b> , 37, 5466-5473	4.1	16
207	Antiviral Agents in Development for Zika Virus Infections. <i>Pharmaceuticals</i> , <b>2019</b> , 12,	5.2	32
206	Strain-Dependent Impact of G and SH Deletions Provide New Insights for Live-Attenuated HMPV Vaccine Development. <i>Vaccines</i> , <b>2019</b> , 7,	5.3	3
205	Synergistic PA and HA mutations confer mouse adaptation of a contemporary A/H3N2 influenza virus. <i>Scientific Reports</i> , <b>2019</b> , 9, 16616	4.9	6
204	Molecular pathway of influenza pan-neuraminidase inhibitor resistance in an immunocompromised patient. <i>Antiviral Therapy</i> , <b>2019</b> , 24, 581-587	1.6	4
203	HUMAN PARAINFLUENZA 2 RELATED ILLNESS AND A DEATH IN A GROUP OF CAPTIVE WESTERN LOWLAND GORILLAS (). <i>Journal of Zoo and Wildlife Medicine</i> , <b>2019</b> , 50, 713-717	0.9	
202	The recruitment of peripheral blood leukocytes to the brain is delayed in susceptible BALB/c compared to resistant C57BL/6 mice during herpes simplex virus encephalitis. <i>Journal of NeuroVirology</i> , <b>2019</b> , 25, 372-383	3.9	3
201	Herpes simplex encephalitis in adult patients with MASP-2 deficiency. <i>PLoS Pathogens</i> , <b>2019</b> , 15, e1008168	16	14
200	The Nonstructural NS1 Protein of Influenza Viruses Modulates Splicing through Host Factor CPSF4. <i>Journal of Virology</i> , <b>2019</b> , 93,	6.6	11

199	Molecular and epidemiologic investigation of a rhinovirus outbreak in a neonatal intensive care unit. <i>Infection Control and Hospital Epidemiology</i> , <b>2019</b> , 40, 245-247	2	1
198	Impact of R152K and R368K neuraminidase catalytic substitutions on in vitro properties and virulence of recombinant A(H1N1)pdm09 viruses. <i>Antiviral Research</i> , <b>2018</b> , 154, 110-115	10.8	3
197	Influenza vaccine effectiveness to prevent influenza-related hospitalizations and serious outcomes in Canadian adults over the 2011/12 through 2013/14 influenza seasons: A pooled analysis from the Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS Network). <i>Vaccine</i> , <b>2018</b> , 36, 2166-2175	4.1	39
196	Both IRF3 and especially IRF7 play a key role to orchestrate an effective cerebral inflammatory response in a mouse model of herpes simplex virus encephalitis. <i>Journal of NeuroVirology</i> , <b>2018</b> , 24, 761-788	3.88	9
195	Predominant role of IPS-1 over TRIF adaptor proteins in early innate immune response against Zika virus in mice. <i>Journal of General Virology</i> , <b>2018</b> , 99, 209-218	4.9	8
194	Evaluation of anticoagulant agents for the treatment of human metapneumovirus infection in mice. <i>Journal of General Virology</i> , <b>2018</b> , 99, 1367-1380	4.9	2
193	In Vitro Properties and Virulence of Contemporary Recombinant Influenza B Viruses Harboring Mutations of Cross-Resistance to Neuraminidase Inhibitors. <i>Viruses</i> , <b>2018</b> , 11,	6.2	5
192	Protease-activated receptor 1 inhibition protects mice against thrombin-dependent respiratory syncytial virus and human metapneumovirus infections. <i>British Journal of Pharmacology</i> , <b>2018</b> , 175, 388-403	8.6	11
191	Resource utilization and cost of influenza requiring hospitalization in Canadian adults: A study from the serious outcomes surveillance network of the Canadian Immunization Research Network. <i>Influenza and Other Respiratory Viruses</i> , <b>2018</b> , 12, 232-240	5.6	19
190	Resistance of Herpesviruses to Antiviral Agents <b>2018</b> , 233-267		
189	Combination Therapy with Oseltamivir and Favipiravir Delays Mortality but Does Not Prevent Oseltamivir Resistance in Immunodeficient Mice Infected with Pandemic A(H1N1) Influenza Virus. <i>Viruses</i> , <b>2018</b> , 10,	6.2	20
188	Comparison of early and recent influenza A(H1N1)pdm09 isolates harboring or not the H275Y neuraminidase mutation, in vitro and in animal models. <i>Antiviral Research</i> , <b>2018</b> , 159, 26-34	10.8	1
187	The quest for a nanoparticle-based vaccine inducing broad protection to influenza viruses. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , <b>2018</b> , 14, 2563-2574	6	13
186	Herpesvirus DNA polymerases: Structures, functions and inhibitors. <i>Virus Research</i> , <b>2017</b> , 234, 177-192	6.4	41
185	Cell Culture Systems To Study Human Herpesvirus 6A/B Chromosomal Integration. <i>Journal of Virology</i> , <b>2017</b> , 91,	6.6	19
184	DNA vaccination protects mice against Zika virus-induced damage to the testes. <i>Nature Communications</i> , <b>2017</b> , 8, 15743	17.4	76
183	Burden of vaccine-preventable pneumococcal disease in hospitalized adults: A Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS) network study. <i>Vaccine</i> , <b>2017</b> , 35, 3647-3654	4.1	22
182	Influenza vaccine effectiveness against influenza-related hospitalization during a season with mixed outbreaks of four influenza viruses: a test-negative case-control study in adults in Canada. <i>BMC Infectious Diseases</i> , <b>2017</b> , 17, 805	4	14

181	Drug Susceptibility and Replicative Capacity of Multidrug-Resistant Recombinant Human Cytomegalovirus Harboring Mutations in and Genes. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,	5.9	14
180	A Review of Clinical Influenza A and B Infections With Reduced Susceptibility to Both Oseltamivir and Zanamivir. <i>Open Forum Infectious Diseases</i> , <b>2017</b> , 4, ofx105	1	26
179	In vitro susceptibility of geographically and temporally distinct Zika viruses to favipiravir and ribavirin. <i>Antiviral Therapy</i> , <b>2017</b> , 22, 613-618	1.6	17
178	The combination of oseltamivir with azithromycin does not show additional benefits over oseltamivir monotherapy in mice infected with influenza A(H1N1)pdm2009 virus. <i>Journal of Medical Virology</i> , <b>2017</b> , 89, 2239-2243	19.7	8
177	Peramivir susceptibilities of recombinant influenza A and B variants selected with various neuraminidase inhibitors. <i>Antiviral Therapy</i> , <b>2017</b> , 22, 711-716	1.6	5
176	The I427T neuraminidase (NA) substitution, located outside the NA active site of an influenza A(H1N1)pdm09 variant with reduced susceptibility to NA inhibitors, alters NA properties and impairs viral fitness. <i>Antiviral Research</i> , <b>2017</b> , 137, 6-13	10.8	9
175	Droplet digital PCR to investigate quasi-species at codons 119 and 275 of the A(H1N1)pdm09 neuraminidase during zanamivir and oseltamivir therapies. <i>Journal of Medical Virology</i> , <b>2017</b> , 89, 737-741 <sup>19.7</sup>	19.7	3
174	The Importance of Frailty in the Assessment of Influenza Vaccine Effectiveness Against Influenza-Related Hospitalization in Elderly People. <i>Journal of Infectious Diseases</i> , <b>2017</b> , 216, 405-414	7	83
173	Antiviral Drug Resistance in Herpesviruses <b>2017</b> , 87-122		2
172	Herpesvirus Resistance to Antiviral Drugs <b>2017</b> , 1185-1211		2
171	Protective role of CX3CR1 signalling in resident cells of the central nervous system during experimental herpes simplex virus encephalitis. <i>Journal of General Virology</i> , <b>2017</b> , 98, 447-460	4.9	10
170	Mutations in the fusion protein heptad repeat domains of human metapneumovirus impact on the formation of syncytia. <i>Journal of General Virology</i> , <b>2017</b> , 98, 1174-1180	4.9	9
169	In vitro and in vivo evidence of a potential A(H1N1)pdm09 antigenic drift mediated by escape mutations in the haemagglutinin Sa antigenic site. <i>Journal of General Virology</i> , <b>2017</b> , 98, 1224-1231	4.9	3
168	Diagnosis of Viral Infections <b>2016</b> , 291-319		1
167	Artesunate demonstrates in vitro synergism with several antiviral agents against human cytomegalovirus. <i>Antiviral Therapy</i> , <b>2016</b> , 21, 535-539	1.6	28
166	Novel Method Based on Real-Time Cell Analysis for Drug Susceptibility Testing of Herpes Simplex Virus and Human Cytomegalovirus. <i>Journal of Clinical Microbiology</i> , <b>2016</b> , 54, 2120-7	9.7	23
165	Standardization of Hemagglutination Inhibition Assay for Influenza Serology Allows for High Reproducibility between Laboratories. <i>Vaccine Journal</i> , <b>2016</b> , 23, 236-42		42
164	Both Cerebral and Hematopoietic Deficiencies in CCR2 Result in Uncontrolled Herpes Simplex Virus Infection of the Central Nervous System in Mice. <i>PLoS ONE</i> , <b>2016</b> , 11, e0168034	3.7	7



163	A Cluster of Three Cases of Hantavirus Pulmonary Syndrome among Canadian Military Personnel. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , <b>2016</b> , 2016, 2757969	2.6	5
162	Structural Insight into NS5 of Zika Virus Leading to the Discovery of MTase Inhibitors. <i>Journal of the American Chemical Society</i> , <b>2016</b> , 138, 16212-16215	16.4	42
161	Antiviral resistance in herpes simplex virus and varicella-zoster virus infections: diagnosis and management. <i>Current Opinion in Infectious Diseases</i> , <b>2016</b> , 29, 654-662	5.4	67
160	The E119D neuraminidase mutation identified in a multidrug-resistant influenza A(H1N1)pdm09 isolate severely alters viral fitness in vitro and in animal models. <i>Antiviral Research</i> , <b>2016</b> , 132, 6-12	10.8	8
159	A collaborative study to establish the 1st WHO International Standard for human cytomegalovirus for nucleic acid amplification technology. <i>Biologicals</i> , <b>2016</b> , 44, 242-251	1.8	60
158	Impact of a large deletion in the neuraminidase protein identified in a laninamivir-selected influenza A/Brisbane/10/2007 (H3N2) variant on viral fitness in vitro and in ferrets. <i>Influenza and Other Respiratory Viruses</i> , <b>2016</b> , 10, 122-6	5.6	4
157	Heterosubtypic protection conferred by the human monoclonal antibody PN-SIA28 against influenza A virus lethal infections in mice. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 59, 2647-53	5.9	1
156	Optimization of Droplet Digital PCR from RNA and DNA extracts with direct comparison to RT-qPCR: Clinical implications for quantification of Oseltamivir-resistant subpopulations. <i>Journal of Virological Methods</i> , <b>2015</b> , 224, 58-66	2.6	80
155	Valacyclovir combined with artesunate or rapamycin improves the outcome of herpes simplex virus encephalitis in mice compared to antiviral therapy alone. <i>Antiviral Research</i> , <b>2015</b> , 123, 105-13	10.8	26
154	Cytomegalovirus quantification in plasma with Abbott RealTime CMV and Roche Cobas Amplicor CMV assays. <i>Journal of Virological Methods</i> , <b>2015</b> , 225, 1-3	2.6	3
153	Targeted Proteomics of Human Metapneumovirus in Clinical Samples and Viral Cultures. <i>Analytical Chemistry</i> , <b>2015</b> , 87, 10247-54	7.8	22
152	Permissive changes in the neuraminidase play a dominant role in improving the viral fitness of oseltamivir-resistant seasonal influenza A(H1N1) strains. <i>Antiviral Research</i> , <b>2015</b> , 114, 57-61	10.8	9
151	Innate immune response during herpes simplex virus encephalitis and development of immunomodulatory strategies. <i>Reviews in Medical Virology</i> , <b>2015</b> , 25, 300-19	11.7	29
150	Effect of in vitro syncytium formation on the severity of human metapneumovirus disease in a murine model. <i>PLoS ONE</i> , <b>2015</b> , 10, e0120283	3.7	7
149	Infiltration Pattern of Blood Monocytes into the Central Nervous System during Experimental Herpes Simplex Virus Encephalitis. <i>PLoS ONE</i> , <b>2015</b> , 10, e0145773	3.7	23
148	E119D Neuraminidase Mutation Conferring Pan-Resistance to Neuraminidase Inhibitors in an A(H1N1)pdm09 Isolate From a Stem-Cell Transplant Recipient. <i>Journal of Infectious Diseases</i> , <b>2015</b> , 212, 1726-34	7	43
147	Contrasting effects of W781V and W780V mutations in helix N of herpes simplex virus 1 and human cytomegalovirus DNA polymerases on antiviral drug susceptibility. <i>Journal of Virology</i> , <b>2015</b> , 89, 4636-44	6.6	11
146	Intrahost dynamics of antiviral resistance in influenza A virus reflect complex patterns of segment linkage, reassortment, and natural selection. <i>MBio</i> , <b>2015</b> , 6,	7.8	43

145	Adjuvant effect of the human metapneumovirus (HMPV) matrix protein in HMPV subunit vaccines. <i>Journal of General Virology</i> , <b>2015</b> , 96, 767-774	4.9	10
144	Impact of the H275Y and I223V Mutations in the Neuraminidase of the 2009 Pandemic Influenza Virus In Vitro and Evaluating Experimental Reproducibility. <i>PLoS ONE</i> , <b>2015</b> , 10, e0126115	3.7	33
143	Oseltamivir-zanamivir combination therapy is not superior to zanamivir monotherapy in mice infected with influenza A(H3N2) and A(H1N1)pdm09 viruses. <i>Antiviral Research</i> , <b>2014</b> , 105, 54-8	10.8	11
142	Impact of potential permissive neuraminidase mutations on viral fitness of the H275Y oseltamivir-resistant influenza A(H1N1)pdm09 virus in vitro, in mice and in ferrets. <i>Journal of Virology</i> , <b>2014</b> , 88, 1652-8	6.6	33
141	Adjuvanted inactivated influenza A(H3N2) vaccines induce stronger immunogenicity in mice and confer higher protection in ferrets than unadjuvanted inactivated vaccines. <i>Vaccine</i> , <b>2014</b> , 32, 5730-9	4.1	12
140	Evolution of oseltamivir resistance mutations in Influenza A(H1N1) and A(H3N2) viruses during selection in experimentally infected mice. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 6398-405	5.9	17
139	Epitope mapping of the 2009 pandemic and the A/Brisbane/59/2007 seasonal (H1N1) influenza virus haemagglutinins using mAbs and escape mutants. <i>Journal of General Virology</i> , <b>2014</b> , 95, 2377-2389	4.9	11
138	Characterization of drug-resistant influenza virus A(H1N1) and A(H3N2) variants selected in vitro with laninamivir. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 5220-8	5.9	37
137	Human metapneumovirus viral load is an important risk factor for disease severity in young children. <i>Journal of Clinical Virology</i> , <b>2014</b> , 60, 133-40	14.5	22
136	Characterization of multiple cytomegalovirus drug resistance mutations detected in a hematopoietic stem cell transplant recipient by recombinant phenotyping. <i>Journal of Clinical Microbiology</i> , <b>2014</b> , 52, 4043-6	9.7	19
135	Antiviral Drug Resistance in Herpesviruses <b>2014</b> , 1-32		
134	Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. <i>Journal of Infectious Diseases</i> , <b>2014</b> , 209, 1219-26	7	22
133	Antiviral drug resistance in herpesviruses other than cytomegalovirus. <i>Reviews in Medical Virology</i> , <b>2014</b> , 24, 186-218	11.7	101
132	Randomized controlled ferret study to assess the direct impact of 2008-09 trivalent inactivated influenza vaccine on A(H1N1)pdm09 disease risk. <i>PLoS ONE</i> , <b>2014</b> , 9, e86555	3.7	19
131	Recent developments with live-attenuated recombinant paramyxovirus vaccines. <i>Reviews in Medical Virology</i> , <b>2013</b> , 23, 15-34	11.7	19
130	Genetic diversity and molecular evolution of the major human metapneumovirus surface glycoproteins over a decade. <i>Journal of Clinical Virology</i> , <b>2013</b> , 58, 541-7	14.5	32
129	Host and viral factors affecting clinical performance of a rapid diagnostic test for respiratory syncytial virus in hospitalized children. <i>Journal of Pediatrics</i> , <b>2013</b> , 163, 911-3	3.6	19
128	Analysis of HHV-6 mutations in solid organ transplant recipients at the onset of cytomegalovirus disease and following treatment with intravenous ganciclovir or oral valganciclovir. <i>Journal of Clinical Virology</i> , <b>2013</b> , 58, 279-82	14.5	10



127	Influenza virus resistance to neuraminidase inhibitors. <i>Antiviral Research</i> , <b>2013</b> , 98, 174-85	10.8	251
126	Virus-like particle vaccine induces cross-protection against human metapneumovirus infections in mice. <i>Vaccine</i> , <b>2013</b> , 31, 2778-85	4.1	32
125	Detection and management of antiviral resistance for influenza viruses. <i>Influenza and Other Respiratory Viruses</i> , <b>2013</b> , 7 Suppl 3, 18-23	5.6	40
124	The combination of valacyclovir with an anti-TNF alpha antibody increases survival rate compared to antiviral therapy alone in a murine model of herpes simplex virus encephalitis. <i>Antiviral Research</i> , <b>2013</b> , 100, 649-53	10.8	18
123	Emergence of an oseltamivir-resistant influenza A/H3N2 virus in an elderly patient receiving a suboptimal dose of antiviral prophylaxis. <i>Journal of Clinical Microbiology</i> , <b>2013</b> , 51, 4234-6	9.7	7
122	Evaluation of Epstein-Barr virus, human herpesvirus 6 (HHV-6), and HHV-8 antiviral drug susceptibilities by use of real-time-PCR-based assays. <i>Journal of Clinical Microbiology</i> , <b>2013</b> , 51, 1244-6	9.7	11
121	Both TRIF and IPS-1 adaptor proteins contribute to the cerebral innate immune response against herpes simplex virus 1 infection. <i>Journal of Virology</i> , <b>2013</b> , 87, 7301-8	6.6	25
120	Evaluation of recombinant 2009 pandemic influenza A (H1N1) viruses harboring zanamivir resistance mutations in mice and ferrets. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2013</b> , 57, 1784-9	5.9	13
119	Reply to "Calibration technologies for correct determination of Epstein-Barr Virus, human herpesvirus 6 (HHV-6), and HHV-8 antiviral drug susceptibilities by use of real-time-PCR-based assays". <i>Journal of Clinical Microbiology</i> , <b>2013</b> , 51, 2014	9.7	
118	Novel method based on "en passant" mutagenesis coupled with a gaussia luciferase reporter assay for studying the combined effects of human cytomegalovirus mutations. <i>Journal of Clinical Microbiology</i> , <b>2013</b> , 51, 3216-24	9.7	28
117	Modulation of protease activated receptor 1 influences human metapneumovirus disease severity in a mouse model. <i>PLoS ONE</i> , <b>2013</b> , 8, e72529	3.7	27
116	Modulation of TLR9 response in a mouse model of herpes simplex virus encephalitis. <i>Antiviral Research</i> , <b>2012</b> , 96, 414-21	10.8	23
115	Molecular and antigenic evolution of human influenza A/H3N2 viruses in Quebec, Canada, 2009-2011. <i>Journal of Clinical Virology</i> , <b>2012</b> , 53, 88-92	14.5	15
114	Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis. <i>Journal of Clinical Virology</i> , <b>2012</b> , 53, 208-13	14.5	37
113	Cross-lineage influenza B and heterologous influenza A antibody responses in vaccinated mice: immunologic interactions and B/Yamagata dominance. <i>PLoS ONE</i> , <b>2012</b> , 7, e38929	3.7	34
112	Seroconversion to seasonal influenza viruses after A(H1N1)pdm09 virus infection, Quebec, Canada. <i>Emerging Infectious Diseases</i> , <b>2012</b> , 18, 1132-4	10.2	6
111	Molecular evolution of respiratory syncytial virus fusion gene, Canada, 2006-2010. <i>Emerging Infectious Diseases</i> , <b>2012</b> , 18, 120-4	10.2	29
110	Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2012</b> , 56, 1208-14	5.9	51

109	Comparison of risk factors for human metapneumovirus and respiratory syncytial virus disease severity in young children. <i>Journal of Infectious Diseases</i> , <b>2012</b> , 206, 178-89	7	103
108	Cross-reactive and vaccine-induced antibody to an emerging swine-origin variant of influenza A virus subtype H3N2 (H3N2v). <i>Journal of Infectious Diseases</i> , <b>2012</b> , 206, 1852-61	7	72
107	Presence of oseltamivir-resistant pandemic A/H1N1 minor variants before drug therapy with subsequent selection and transmission. <i>Journal of Infectious Diseases</i> , <b>2012</b> , 206, 1504-11	7	56
106	Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice. <i>Vaccine Journal</i> , <b>2012</b> , 19, 209-18		35
105	The H275Y neuraminidase mutation of the pandemic A/H1N1 influenza virus lengthens the eclipse phase and reduces viral output of infected cells, potentially compromising fitness in ferrets. <i>Journal of Virology</i> , <b>2012</b> , 86, 10651-60	6.6	72
104	Therapeutic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H275Y neuraminidase mutation. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2012</b> , 56, 4375-80	5.9	16
103	Impact of deficiency in CCR2 and CX3CR1 receptors on monocytes trafficking in herpes simplex virus encephalitis. <i>Journal of General Virology</i> , <b>2012</b> , 93, 1294-1304	4.9	21
102	Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children. <i>Vaccine</i> , <b>2011</b> , 30, 35-41	4.1	33
101	Parenteral peramivir treatment for Oseltamivir-resistant 2009 pandemic influenza A H1N1 viruses. <i>Journal of Infectious Diseases</i> , <b>2011</b> , 204, 1641-2; author's reply 1642-3	7	10
100	Assessing the in vitro fitness of an oseltamivir-resistant seasonal A/H1N1 influenza strain using a mathematical model. <i>PLoS ONE</i> , <b>2011</b> , 6, e14767	3.7	42
99	Reduced airborne transmission of oseltamivir-resistant pandemic A/H1N1 virus in ferrets. <i>Antiviral Therapy</i> , <b>2011</b> , 16, 775-9	1.6	14
98	Risk factors for hospitalization and severe outcomes of 2009 pandemic H1N1 influenza in Quebec, Canada. <i>Influenza and Other Respiratory Viruses</i> , <b>2011</b> , 5, 247-55	5.6	72
97	Systematic review of influenza resistance to the neuraminidase inhibitors. <i>BMC Infectious Diseases</i> , <b>2011</b> , 11, 134	4	147
96	Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors. <i>Journal of Infectious Diseases</i> , <b>2011</b> , 203, 25-31	7	122
95	Influenza drug resistance. <i>Seminars in Respiratory and Critical Care Medicine</i> , <b>2011</b> , 32, 409-22	3.9	58
94	The I222V neuraminidase mutation has a compensatory role in replication of an oseltamivir-resistant influenza virus A/H3N2 E119V mutant. <i>Journal of Clinical Microbiology</i> , <b>2011</b> , 49, 715-7	9.7	35
93	Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2011</b> , 55, 4019-27	5.9	23
92	Long-term impairment of <i>Streptococcus pneumoniae</i> lung clearance is observed after initial infection with influenza A virus but not human metapneumovirus in mice. <i>Journal of General Virology</i> , <b>2011</b> , 92, 1662-1665	4.9	12

91	Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2011</b> , 55, 459-72	5.9	344
90	Design considerations in building in silico equivalents of common experimental influenza virus assays. <i>Autoimmunity</i> , <b>2011</b> , 44, 282-93	3	23
89	Role of permissive neuraminidase mutations in influenza A/Brisbane/59/2007-like (H1N1) viruses. <i>PLoS Pathogens</i> , <b>2011</b> , 7, e1002431	7.6	58
88	Evaluation of serological diagnostic methods for the 2009 pandemic influenza A (H1N1) virus. <i>Vaccine Journal</i> , <b>2011</b> , 18, 520-2		19
87	The 2009 pandemic H1N1 D222G hemagglutinin mutation alters receptor specificity and increases virulence in mice but not in ferrets. <i>Journal of Infectious Diseases</i> , <b>2011</b> , 204, 1008-16	7	34
86	Effect of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A(H1N1) viruses. <i>Journal of Infectious Diseases</i> , <b>2010</b> , 201, 740-5	7	93
85	Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H274Y neuraminidase mutation. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2010</b> , 54, 2819-22	5.9	15
84	Household transmission of the 2009 pandemic A/H1N1 influenza virus: elevated laboratory-confirmed secondary attack rates and evidence of asymptomatic infections. <i>Clinical Infectious Diseases</i> , <b>2010</b> , 51, 1033-41	11.6	92
83	Viral pathogens including human metapneumovirus are the primary cause of febrile respiratory illness in HIV-infected adults receiving antiretroviral therapy. <i>Journal of Infectious Diseases</i> , <b>2010</b> , 201, 297-301	7	20
82	Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada. <i>PLoS Medicine</i> , <b>2010</b> , 7, e1000258	11.6	222
81	Oseltamivir-resistant pandemic A/H1N1 virus is as virulent as its wild-type counterpart in mice and ferrets. <i>PLoS Pathogens</i> , <b>2010</b> , 6, e1001015	7.6	78
80	Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis. <i>Journal of Clinical Virology</i> , <b>2010</b> , 47, 321-4	14.5	33
79	Contrasting effects on ganciclovir susceptibility and replicative capacity of two mutations at codon 466 of the human cytomegalovirus UL97 gene. <i>Journal of Clinical Virology</i> , <b>2010</b> , 49, 296-8	14.5	14
78	Recombinant phenotyping of cytomegalovirus sequence variants detected after 200 or 100 days of valganciclovir prophylaxis. <i>Transplantation</i> , <b>2010</b> , 90, 1409-13	1.8	20
77	Opposite effect of two cytomegalovirus DNA polymerase mutations on replicative capacity and polymerase activity. <i>Antiviral Therapy</i> , <b>2010</b> , 15, 579-86	1.6	15
76	Prophylactic and therapeutic benefits of a monoclonal antibody against the fusion protein of human metapneumovirus in a mouse model. <i>Antiviral Research</i> , <b>2010</b> , 88, 31-7	10.8	29
75	Neurovirulence and latency of drug-resistant clinical herpes simplex viruses in animal models. <i>Journal of Medical Virology</i> , <b>2010</b> , 82, 1000-6	19.7	15
74	The distinguishing features of human metapneumovirus and respiratory syncytial virus. <i>Reviews in Medical Virology</i> , <b>2010</b> , 20, 245-60	11.7	62

73	Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2009</b> , 53, 791-3	5.9	11
72	A novel neuraminidase deletion mutation conferring resistance to oseltamivir in clinical influenza A/H3N2 virus. <i>Journal of Infectious Diseases</i> , <b>2009</b> , 199, 180-3	7	34
71	Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis. <i>New England Journal of Medicine</i> , <b>2009</b> , 361, 2296-7	59.2	185
70	Comparison of automated microarray detection with real-time PCR assays for detection of respiratory viruses in specimens obtained from children. <i>Journal of Clinical Microbiology</i> , <b>2009</b> , 47, 743-50	8.7	78
69	Infection with human metapneumovirus predisposes mice to severe pneumococcal pneumonia. <i>Journal of Virology</i> , <b>2009</b> , 83, 1341-9	6.6	64
68	Importance of viral and bacterial infections in chronic obstructive pulmonary disease exacerbations. <i>Journal of Clinical Virology</i> , <b>2009</b> , 46, 129-33	14.5	83
67	Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. <i>Antiviral Therapy</i> , <b>2009</b> , 14, 697-704	1.6	22
66	Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. <i>Antiviral Therapy</i> , <b>2009</b> , 14, 697-704	1.6	69
65	Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes. <i>Antiviral Research</i> , <b>2008</b> , 77, 163-6	10.8	56
64	Human respiratory syncytial virus and other viral infections in infants receiving palivizumab. <i>Journal of Clinical Virology</i> , <b>2008</b> , 42, 52-7	14.5	31
63	Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. <i>Vaccine</i> , <b>2008</b> , 26, 3395-403	4.1	139
62	Effect of pretreatment with toll-like receptor agonists in a mouse model of herpes simplex virus type 1 encephalitis. <i>Journal of Infectious Diseases</i> , <b>2008</b> , 198, 664-72	7	54
61	Identification and evaluation of a highly effective fusion inhibitor for human metapneumovirus. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2008</b> , 52, 279-87	5.9	46
60	Inhibition of Human Metapneumovirus Replication by Small Interfering RNA. <i>Antiviral Therapy</i> , <b>2008</b> , 13, 821-832	1.6	18
59	The Prophylactic Administration of a Monoclonal Antibody against Human Metapneumovirus Attenuates viral Disease and Airways Hyperresponsiveness in Mice. <i>Antiviral Therapy</i> , <b>2008</b> , 13, 39-46	1.6	19
58	Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir. <i>Antiviral Research</i> , <b>2007</b> , 74, 159-62	10.8	56
57	Tumor necrosis factor-alpha and interleukin-1 beta play a critical role in the resistance against lethal herpes simplex virus encephalitis. <i>Journal of Infectious Diseases</i> , <b>2007</b> , 196, 853-60	7	121
56	Enhanced lung disease and Th2 response following human metapneumovirus infection in mice immunized with the inactivated virus. <i>Journal of General Virology</i> , <b>2007</b> , 88, 3391-3400	4.9	34

55	An outbreak of severe respiratory tract infection due to human metapneumovirus in a long-term care facility. <i>Clinical Infectious Diseases</i> , <b>2007</b> , 44, 1152-8	11.6	157
54	Delayed but not early glucocorticoid treatment protects the host during experimental herpes simplex virus encephalitis in mice. <i>Journal of Infectious Diseases</i> , <b>2007</b> , 195, 817-25	7	65
53	Human metapneumovirus: enhanced pulmonary disease in cotton rats immunized with formalin-inactivated virus vaccine and challenged. <i>Vaccine</i> , <b>2007</b> , 25, 5034-40	4.1	41
52	Influenza virus susceptibility and resistance to oseltamivir. <i>Antiviral Therapy</i> , <b>2007</b> , 12, 603-16	1.6	73
51	Influenza Virus Susceptibility and Resistance to Oseltamivir. <i>Antiviral Therapy</i> , <b>2007</b> , 12, 603-616	1.6	111
50	Treatment of respiratory virus infections. <i>Antiviral Research</i> , <b>2006</b> , 70, 1-16	10.8	49
49	Distribution and clinical impact of human respiratory syncytial virus genotypes in hospitalized children over 2 winter seasons. <i>Journal of Infectious Diseases</i> , <b>2006</b> , 193, 54-8	7	74
48	Characterization of human cytomegalovirus (HCMV) UL97 mutations found in a valganciclovir/oral ganciclovir prophylactic trial by use of a bacterial artificial chromosome containing the HCMV genome. <i>Journal of Infectious Diseases</i> , <b>2006</b> , 194, 579-83	7	22
47	Effect of ribavirin and glucocorticoid treatment in a mouse model of human metapneumovirus infection. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2006</b> , 50, 774-7	5.9	88
46	Thymidine kinase mutations conferring acyclovir resistance in herpes simplex type 1 recombinant viruses. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2006</b> , 50, 3889-92	5.9	19
45	Human metapneumovirus infection induces long-term pulmonary inflammation associated with airway obstruction and hyperresponsiveness in mice. <i>Journal of Infectious Diseases</i> , <b>2006</b> , 193, 1634-42	7	75
44	Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. <i>Clinical Infectious Diseases</i> , <b>2006</b> , 43, 1555-61	11.6	162
43	Role of helix P of the human cytomegalovirus DNA polymerase in resistance and hypersusceptibility to the antiviral drug foscarnet. <i>Journal of Virology</i> , <b>2006</b> , 80, 1440-50	6.6	26
42	Longitudinal evaluation of herpes simplex virus DNA load during episodes of herpes labialis. <i>Journal of Clinical Virology</i> , <b>2006</b> , 37, 248-51	14.5	21
41	Three-dimensional modeling of cytomegalovirus DNA polymerase and preliminary analysis of drug resistance. <i>Proteins: Structure, Function and Bioinformatics</i> , <b>2006</b> , 64, 301-7	4.2	19
40	Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. <i>Antiviral Therapy</i> , <b>2006</b> , 11, 971-6	1.6	80
39	Impact of Neuraminidase Mutations Conferring Influenza Resistance to Neuraminidase Inhibitors in the N1 and N2 Genetic Backgrounds. <i>Antiviral Therapy</i> , <b>2006</b> , 11, 971-976	1.6	122
38	A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients. <i>American Journal of Transplantation</i> , <b>2005</b> , 5, 1462-8	8.7	80

37	Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis. <i>Journal of Medical Virology</i> , <b>2005</b> , 77, 425-9	19.7	57
36	Pathogenesis of human metapneumovirus lung infection in BALB/c mice and cotton rats. <i>Journal of Virology</i> , <b>2005</b> , 79, 8894-903	6.6	88
35	Generation and characterization of recombinant influenza A (H1N1) viruses harboring amantadine resistance mutations. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2005</b> , 49, 556-9	5.9	144
34	Global genetic diversity of human metapneumovirus fusion gene. <i>Emerging Infectious Diseases</i> , <b>2004</b> , 10, 1154-7	10.2	111
33	Sequence polymorphism of the predicted human metapneumovirus G glycoprotein. <i>Journal of General Virology</i> , <b>2004</b> , 85, 679-686	4.9	57
32	Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. <i>Journal of Infectious Diseases</i> , <b>2004</b> , 189, 1615-8	7	140
31	Human metapneumovirus: a new player among respiratory viruses. <i>Clinical Infectious Diseases</i> , <b>2004</b> , 38, 983-90	11.6	143
30	A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus. <i>Antiviral Therapy</i> , <b>2004</b> , 9, 577-81	1.6	35
29	A Reverse Genetics Study of Resistance to Neuraminidase Inhibitors in An Influenza A/H1N1 Virus. <i>Antiviral Therapy</i> , <b>2004</b> , 9, 577-581	1.6	46
28	Discordant phenotypes and genotypes of cytomegalovirus (CMV) in patients with AIDS and relapsing CMV retinitis. <i>Aids</i> , <b>2003</b> , 17, 337-41	3.5	15
27	Drug resistance patterns of recombinant herpes simplex virus DNA polymerase mutants generated with a set of overlapping cosmids and plasmids. <i>Journal of Virology</i> , <b>2003</b> , 77, 7820-9	6.6	67
26	Human metapneumovirus infections in hospitalized children. <i>Emerging Infectious Diseases</i> , <b>2003</b> , 9, 634-40	10.2	352
25	Genetic diversity between human metapneumovirus subgroups. <i>Virology</i> , <b>2003</b> , 315, 1-9	3.6	191
24	Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro. <i>Antiviral Research</i> , <b>2003</b> , 60, 51-9	10.8	157
23	Sequence analysis of the N, P, M and F genes of Canadian human metapneumovirus strains. <i>Virus Research</i> , <b>2003</b> , 93, 51-62	6.4	100
22	Evaluation of susceptibility of human herpesvirus 8 to antiviral drugs by quantitative real-time PCR. <i>Journal of Clinical Microbiology</i> , <b>2003</b> , 41, 3897-900	9.7	32
21	Comparative evaluation of real-time PCR assays for detection of the human metapneumovirus. <i>Journal of Clinical Microbiology</i> , <b>2003</b> , 41, 3631-5	9.7	99
20	Respiratory tract reinfections by the new human Metapneumovirus in an immunocompromised child. <i>Emerging Infectious Diseases</i> , <b>2002</b> , 8, 976-8	10.2	184



19	Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors. <i>Antiviral Research</i> , <b>2002</b> , 54, 143-7	10.8	57
18	Divergent evolution of hemagglutinin and neuraminidase genes in recent influenza A:H3N2 viruses isolated in Canada. <i>Journal of Medical Virology</i> , <b>2002</b> , 67, 589-95	19.7	32
17	Quantification of human herpesvirus 8 by real-time PCR in blood fractions of AIDS patients with Kaposi's sarcoma and multicentric Castleman's disease. <i>Journal of Medical Virology</i> , <b>2002</b> , 68, 399-403	19.7	37
16	Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy. <i>Journal of Medical Virology</i> , <b>2002</b> , 67, 88-91	19.7	27
15	Intranasal herpes simplex virus type 2 inoculation causes a profound thymidine kinase dependent cerebral inflammatory response in the mouse hindbrain. <i>European Journal of Neuroscience</i> , <b>2002</b> , 16, 29-43	3.5	38
14	Characterization of 2 influenza A(H3N2) clinical isolates with reduced susceptibility to neuraminidase inhibitors due to mutations in the hemagglutinin gene. <i>Journal of Infectious Diseases</i> , <b>2002</b> , 186, 1074-80	7	52
13	Prolonged excretion of amantadine-resistant influenza a virus quasi species after cessation of antiviral therapy in an immunocompromised patient. <i>Clinical Infectious Diseases</i> , <b>2002</b> , 34, E23-5	11.6	64
12	Role of picornaviruses in flu-like illnesses of adults enrolled in an oseltamivir treatment study who had no evidence of influenza virus infection. <i>Journal of Clinical Microbiology</i> , <b>2002</b> , 40, 330-4	9.7	13
11	Virological features and clinical manifestations associated with human metapneumovirus: a new paramyxovirus responsible for acute respiratory-tract infections in all age groups. <i>Journal of Infectious Diseases</i> , <b>2002</b> , 186, 1330-4	7	460
10	Characterization of human metapneumoviruses isolated from patients in North America. <i>Journal of Infectious Diseases</i> , <b>2002</b> , 185, 1660-3	7	319
9	Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. <i>Drug Resistance Updates</i> , <b>2002</b> , 5, 88-114	23.2	238
8	Highly reliable heterologous system for evaluating resistance of clinical herpes simplex virus isolates to nucleoside analogues. <i>Journal of Virology</i> , <b>2001</b> , 75, 3105-10	6.6	50
7	Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. <i>Journal of Infectious Diseases</i> , <b>2001</b> , 184, 1598-602	7	111
6	Rapid antiviral effect of inhaled zanamivir in the treatment of naturally occurring influenza in otherwise healthy adults. <i>Journal of Infectious Diseases</i> , <b>2000</b> , 181, 1471-4	7	65
5	Characterization of the DNA polymerase and thymidine kinase genes of herpes simplex virus isolates from AIDS patients in whom acyclovir and foscarnet therapy sequentially failed. <i>Journal of Infectious Diseases</i> , <b>1999</b> , 180, 487-90	7	84
4	Emergence and prevalence of cytomegalovirus UL97 mutations associated with ganciclovir resistance in AIDS patients. <i>Aids</i> , <b>1998</b> , 12, 125-9	3.5	34
3	Quantitation of cytomegalovirus: methodologic aspects and clinical applications. <i>Clinical Microbiology Reviews</i> , <b>1998</b> , 11, 533-54	34	307
2	Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. <i>Journal of Infectious Diseases</i> , <b>1997</b> , 175, 1087-92	7	128

- 1 A case of ganciclovir-resistant cytomegalovirus (CMV) retinitis in a patient with AIDS: longitudinal molecular analysis of the CMV viral load and viral mutations in blood compartments. *Aids*, **1997**, 11, 867-73 16